Profil bibliographique

Sarah B. Goldberg

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

512Publications signalées

13406Citations signalées

3Affiliations récentes

Institutions déclarées

Yale Cancer Center Yale University Medical Oncology Hematology Consultants

Domaines associés

Lung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersLung Cancer Research StudiesLung Cancer Diagnosis and Treatment

Publications récentes

Accès ouvert 2026 otherOpenAlex

Data from Genomic Profiling of Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study

Helena A. Yu, Kwan Ho Tang, Aleksandra Markovets, Ryan J. Hartmaier et autres

0 citations

2026 articleOpenAlex

Matched targeted therapy use after broad genomic profiling in advanced Non-Small cell lung cancer

Xiao Wang, Jessica B. Long, John Rothen, Akintunde O Aremu et autres

0 citationsJNCI Journal of the National Cancer Institute

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Data from Genomic Profiling of Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study

Helena A. Yu, Kwan Ho Tang, Aleksandra Markovets, Ryan J. Hartmaier et autres

0 citations

Accès ouvert 2026 articleOpenAlex

Osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD

Jonathan W. Goldman, Jonathan W. Riess, Byoung Chul Cho, Sarah B. Goldberg et autres

0 citationsClinical Lung Cancer

Accès ouvert 2026 articleOpenAlex

Osimertinib plus Gefitinib in Patients with EGFR -Mutated Advanced Non–Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD

Sarah B. Goldberg, Myung‐Ju Ahn, Christina S. Baik, Javier de Castro et autres

1 citationClinical Cancer Research

2026 conference-abstractOpenAlex

PP01.18: Different Lung Cancer-Associated ERBB2 Variants Exhibit Distinct Therapeutic Vulnerabilities

Paul Stockhammer, Erinda Aidoo, Keita Maemura, Lucy W. Kim et autres

0 citationsJournal of Thoracic Oncology

2026 articleOpenAlex

Medical Management of Non–Small Cell Lung Cancer Brain Metastases in the Modern Era

Benjamin Y. Lu, Sarah B. Goldberg

0 citationsThe Cancer Journal

2026 articleOpenAlex

Treatment of Non–Small Cell Lung Cancer

Sarah B. Goldberg, Roy S. Herbst

0 citationsThe Cancer Journal

2026 articleOpenAlex

Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD

Isamu Okamoto, Byoung Chul Cho, Sarah B. Goldberg, Jonathan W. Goldman et autres

3 citationsLung Cancer

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S1 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S3 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table S1 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.